Financial
Parent Johnson & Johnson (JNJ) group FY2025 revenue $94.19bn (+6.0%); pre-tax margin 34.6%; net income $26.80bn.
MedTech segment sales $33.79bn (+6.1%).
Johnson & Johnson MedTech
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongOwned by Johnson & Johnson (JNJ)
Parent Johnson & Johnson (JNJ) group FY2025 revenue $94.19bn (+6.0%); pre-tax margin 34.6%; net income $26.80bn.
MedTech segment sales $33.79bn (+6.1%).
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$94.2bn | +6.0% | — | US$26.8bn | Johnson & Johnson group |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Not yet researched.
Cyber & information governance
Not yet researched.
Regulatory & clinical safety
Not yet researched.
Contract performance
Not yet researched.
Competitors
No competitors linked yet.